anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cycloserine
Trial phase: Phase 3
ATC code: J04AB01
SMILES: N[C@@H]1CONC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Patients were given 50 mg of D-Cycloserine daily in addition to their treatment as usual with conventional neuroleptics.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Schizophrenia as per DSM IV criteria
Have been treated for at least 6 months with any conventional neuroleptic
Have prominent negative symptoms as defined by a total score of 40 or greater on the scale for the assessment of negative symptoms (SANS)

Exclusion Criteria:

Active alcohol or drug abuse
Unstable Medical Illness, seizure disorder, or other serious neurological disorder
Pregnant or Nursing
Unable to complete a cognitive battery
Intervention: Lurasidone
Trial phase: Phase 2
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Lurasdione 20 mg oral tablets
Eligibility criteria:
Inclusion criteria:

Successful completion of participation in protocol #D1050049

Exclusion criteria:

Substance abuse
Prolactin level of ≥200ng/mL at baseline
Pregnancy
Intervention: Lurasidone
Trial phase: Phase 2
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Lurasidone 80mg oral tablets
Eligibility criteria:
Inclusion criteria:

Successful completion of participation in protocol #D1050049

Exclusion criteria:

Substance abuse
Prolactin level of ≥200ng/mL at baseline
Pregnancy
Intervention: Travoprost
Trial phase: Phase 3
ATC code: S01EE04
SMILES: CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(C(F)(F)F)c2)[C@H](O)C[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 502
Group description: Travoprost (0.004%)
Eligibility criteria:
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Intervention: Ursodeoxycholic acid
Trial phase: Phase 2 | Phase 3
ATC code: A05AA02
SMILES: [H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@@]3(C)[C@@]([H])(CC[C@]3([H])[C@H](C)CCC(=O)O)[C@]1([H])[C@@H](O)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 150
Group description: Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
Eligibility criteria:
Chronic cholestatic disease of at least six months' duration.
Serum alkaline phosphatase at least 1 ½ times the upper limits of normal.
Retrograde, operative, percutaneous, or magnetic resonance cholangiography demonstrating intrahepatic and/or extrahepatic biliary duct obstruction, beading, or narrowing consistent with PSC within one year of the study entry.
Liver biopsy in the previous one year which is available for review and compatible with the diagnosis of PSC. Compatible biopsy features include fibrous cholangitis, ductopenia with periportal inflammation and biliary fibrosis.
Intervention: Decitabine
Trial phase: Phase 2
ATC code: L01BC08
SMILES: Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 93
Group description: 20 mg/m2 IV over 1 hour daily for 5 days
Eligibility criteria:
Inclusion Criteria:

MDS and 5% or more marrow blasts, or IPSS risk intermediate 1-2 or high risk; or chronic myelomonocytic leukemia
Performance status 0-2 (Eastern Cooperative Oncology Group (ECOG) scale); adequate hepatic (bilirubin < 2 mg/dl) and renal functions (creatinine <2mg/dl); New York Heart Association (NYHA) cardiac status III-IV excluded.
Signed informed consent
No prior intensive combination chemotherapy or high-dose ara-C (>/= 1g/m2 per dose). Prior biologic therapies, targeted therapies and single agent chemotherapy allowed.
Patients must have been off chemotherapy for 2 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease. Use of Hydroxyurea for patients with rapidly proliferative disease is allowed for the first two weeks on therapy.

Exclusion Criteria:

Nursing and pregnant females are excluded. Patients of childbearing potential should practice effective methods of contraception. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Patients with active and uncontrolled infections
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
Intervention: Lurasidone
Trial phase: Phase 2
ATC code: N05AE05
SMILES: [H][C@@]12C(=O)N(C[C@@H]3CCCC[C@H]3CN3CCN(c4nsc5ccccc45)CC3)C(=O)[C@]1([H])[C@H]1CC[C@@H]2C1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 90
Group description: 2 40 mg lurasidone tablets taken once/day
Eligibility criteria:
Inclusion Criteria:

Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV
The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment
If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception

Exclusion Criteria:

The patient has used an investigational drug within the past 30 days
The patient has participated in a previous study of this compound
Intervention: 5'-[[(3S)-3-Amino-3-carboxypropyl]methylsulfonio]-5'-deoxy-Adenosine tosylate
Trial phase: Phase 2
SMILES: C[S+](CCC(N)C(=O)O)CC1OC(n2cnc3c(N)ncnc32)C(O)C1O.Cc1ccc(S(=O)(=O)[O-])cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: Participants receiving the oral SAMe tosylate
Eligibility criteria:
Inclusion Criteria:

Major depressive disorder
Use of an SSRI for at least 6 weeks prior to study entry with partial or no response

Exclusion Criteria:

History of psychosis
Allergy to SAMe
Alcohol or drug abuse in the past 3 months prior to study entry
Intervention: Valganciclovir
Trial phase: Not Applicable
ATC code: J05AB14
SMILES: CC(C)C(N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Patients receive oral valganciclovir twice daily for 3 weeks and then once daily for 21 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed for 1 month after completion of therapy. Patients with responding disease are followed monthly for up to 1 year.
Eligibility criteria:
DISEASE CHARACTERISTICS:

Histologically confirmed classic Kaposi's sarcoma (KS) involving the skin

Non-HIV-associated disease

HIV negative

Measurable disease

At least 8 KS lesions with ≥ 5 marker lesions measurable in 2 dimensions AND ≥ 3 other lesions measuring ≥ 1 cm in diameter

Two 3 mm punch biopsies of a non-marker lesion entirely composed of KS
Irradiated cutaneous lesions may not be used as indicator lesions
No known active visceral KS or symptomatic KS-related edema that would preclude function or require cytotoxic chemotherapy

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

Karnofsky 70-100%

Life expectancy

At least 12 months

Hematopoietic

Hemoglobin ≥ 8 g/dL
Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3

Hepatic

Bilirubin ≤ 1.5 times upper limit of normal (ULN)
AST and ALT ≤ 3 times ULN

Renal

Creatinine clearance ≥ 50 mL/min

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier contraception during and for 3 months after study participation
No hypersensitivity to valganciclovir or ganciclovir
No other neoplasia requiring cytotoxic therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

More than 4 weeks since prior biological therapy for KS
No concurrent immunotherapy

Chemotherapy

More than 4 weeks since prior chemotherapy for KS
No concurrent chemotherapy

Endocrine therapy

No concurrent corticosteroid treatment except for replacement doses (equivalent to 20 mg of hydrocortisone per day)

Radiotherapy

See Disease Characteristics
More than 4 weeks since prior radiotherapy for KS
No concurrent radiotherapy

Surgery

Not specified

Other

More than 14 days since prior acute treatment for infection (other than oral thrush or genital herpes) or other serious medical illness
More than 60 days since prior local therapy for any KS indicator lesion unless the lesion showed documented progression since treatment
More than 4 weeks since prior local therapy for KS
More than 4 weeks since prior investigational agents
More than 4 weeks since other prior antineoplastic therapy for KS
No other concurrent antiviral therapy
No other concurrent investigational agents
No other concurrent systemic therapy for KS
Intervention: Oratecan
Trial phase: Phase 2
SMILES: CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: irinotecan hydrochloride
Eligibility criteria:
Inclusion

Histologically confirmed medullary thyroid cancer
Metastatic or inoperable locoregional disease
Measurable disease by CT scan
18 years and over
ECOG PS 0-1

Adequate lab functions including:

Granulocyte count > 1,000/mm^3
Platelet count > 100,000/mm^3
Bilirubin < 1.5 mg/dL
ALT and AST < 2.5 times upper limit of normal
No unstable or uncompensated hepatic disease
Creatinine clearance > 60 mL/min
No unstable or uncompensated renal disease
Negative pregnancy test
More than 3 months since prior biologic therapy
More than 3 months since prior chemotherapy
No prior radiotherapy to > 25% of bone marrow
More than 3 months since prior radiotherapy
Recovered from prior oncologic or other major surgery
More than 30 days since prior non-approved or investigational drugs

Exclusion:

Patients with elevated calcitonin levels as the only measurement of disease are not eligible
Unstable or uncompensated cardiovascular disease
Unstable or uncompensated respiratory disease
Pregnant or nursing
Diarrhea ≥ grade 2 (antidiarrheals allowed)
Other severe or uncontrolled systemic disease
Other malignancy within the past 5 years except squamous cell or basal cell skin cancer or cervical cancer
Illness that would preclude study participation
Significant clinical disorder or laboratory finding that would preclude study participation
Intervention: Decitabine
Trial phase: Phase 2
ATC code: L01BC08
SMILES: Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: 20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
Eligibility criteria:
Inclusion Criteria:

MDS and 5% or more marrow blasts, or IPSS risk intermediate 1-2 or high risk; or chronic myelomonocytic leukemia. Patients must have failed therapy with azacytidine.
Performance status 0-2 (ECOG scale); adequate hepatic (bilirubin < 2 mg/dl) and renal functions (creatinine <2mg/dl); New York Heart Association (NYHA)cardiac status III-IV excluded.
Signed informed consent.
No prior intensive combination chemotherapy or high-dose ara-C (>/= 1g/m*2 per dose). Prior biologic therapies, targeted therapies and single agent chemotherapy allowed.
Patients must have been off chemotherapy for 2 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease. Use of hydroxyurea for patients with rapidly proliferative disease is allowed for the first two weeks on therapy.

Exclusion Criteria:

Nursing and pregnant females are excluded. Patients of childbearing potential should practice effective methods of contraception. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Patients with active and uncontrolled infections.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
Intervention: Chlordiazepoxide
Trial phase: Not Applicable
ATC code: N05BA02
SMILES: CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: Patients with FDG-positive carotid artery and/or aorta who received simvastatin and diet therapy
Eligibility criteria:
Inclusion Criteria:

Protocol 1: patients who had carotid atherosclerosis detected by carotid ultrasound.
Protocol 2: patients who underwent FDG-PET for cancer screening and had vascular FDG uptakes

Exclusion Criteria:

Active inflammatory diseases
Dyslipidemia under medications
Uncontrolled diabetes mellitus, vasculitis, symptomatic coronary artery disease, symptomatic cerebrovascular diseases
Known systemic disorders such as hepatic, renal, hematopoietic, and malignant diseases
Intervention: Heliox
Trial phase: Phase 3
SMILES: O=O.[He]
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 72
Group description: heliox-driven nebulizations for children with moderate to severe bronchiolitis
Eligibility criteria:
Inclusion Criteria:

Any child 2-12 months old seen in the emergency department.
A clinical bronchiolitis score > 3 by modified Wood's Clinical Bronchiolitis Score (M-WCBS).
Diagnostic criteria of bronchiolitis includes tachypnea, cough, prolonged expiratory phase, wheezing, rales, chest retractions, and hyperinflation of lungs on chest radiograph. After consenting a patient to the study, respiratory syncytial virus (RSV) infection will be tested by rapid enzyme-linked immunoabsorbent assay of nasal secretions.

Exclusion Criteria:

No child will be excluded based on race or gender
Patients under the age of 2 months or greater than 12 months
Patients with cyanotic heart disease
Patients with lobar pneumonia, defined by results of chest radiographs.
The presence of interstitial disease or diffuse patchy marking consistent with atelectasis on chest radiographs will not exclude patients.
Patients with croup.
Patients with foreign body aspiration.
Patients with history of cystic fibrosis, bronchopulmonary dysplasia or other chronic lung disease.
Patients with liver or renal disease.
Patients with sickle cell anemia.
Patients requiring mechanical ventilation.
Patients who develop supraventricular tachycardia secondary to racemic epinephrine administration.
Patients with tracheomalacia or bronchomalacia.
Patients who had received bronchodilators within 2 hours of initiation of the study.
Patients who had received systemic corticosteroids within 72 hours of enrollment
Patients who suffered from persistent airway hyperreactivity in the 3 months before the study.
Patients who do not tolerate the nasal cannulae for 45 out of 60 minutes.
Intervention: Oxygen
Trial phase: Phase 3
ATC code: V03AN01
SMILES: O=O
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 72
Group description: Oxygen nebulizations for children with moderate to severe bronchiolitis
Eligibility criteria:
Inclusion Criteria:

Any child 2-12 months old seen in the emergency department.
A clinical bronchiolitis score > 3 by modified Wood's Clinical Bronchiolitis Score (M-WCBS).
Diagnostic criteria of bronchiolitis includes tachypnea, cough, prolonged expiratory phase, wheezing, rales, chest retractions, and hyperinflation of lungs on chest radiograph. After consenting a patient to the study, respiratory syncytial virus (RSV) infection will be tested by rapid enzyme-linked immunoabsorbent assay of nasal secretions.

Exclusion Criteria:

No child will be excluded based on race or gender
Patients under the age of 2 months or greater than 12 months
Patients with cyanotic heart disease
Patients with lobar pneumonia, defined by results of chest radiographs.
The presence of interstitial disease or diffuse patchy marking consistent with atelectasis on chest radiographs will not exclude patients.
Patients with croup.
Patients with foreign body aspiration.
Patients with history of cystic fibrosis, bronchopulmonary dysplasia or other chronic lung disease.
Patients with liver or renal disease.
Patients with sickle cell anemia.
Patients requiring mechanical ventilation.
Patients who develop supraventricular tachycardia secondary to racemic epinephrine administration.
Patients with tracheomalacia or bronchomalacia.
Patients who had received bronchodilators within 2 hours of initiation of the study.
Patients who had received systemic corticosteroids within 72 hours of enrollment
Patients who suffered from persistent airway hyperreactivity in the 3 months before the study.
Patients who do not tolerate the nasal cannulae for 45 out of 60 minutes.
Intervention: Degarelix
Trial phase: Phase 2
ATC code: L02BX02
SMILES: CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Degarelix 40 mg (10 mg/mL)
Eligibility criteria:
Inclusion Criteria:

Each patient must meet the following inclusion criteria before entry into the study:

Has given written consent before any study related activity is performed. A study related activity is defined as any procedure that would not have been performed during the normal management of the patient.
Has had sufficient testosterone suppression (as defined in the withdrawal criteria of FE200486 CS06) for at least 28 days.

Exclusion Criteria:

Any patient meeting any of the following exclusion criteria will not be entered into the study:

Has been withdrawn from Study FE200486 CS06 due to an adverse event, failure to achieve at least 28 days of testosterone suppression, insufficient prostate-specific antigen (PSA) suppression as defined in Study FE200486 CS06 in the absence of concomitant rise in testosterone level or non-compliance with protocol required procedures.
Requires hormonal therapy for neoadjuvant purposes.
Requires treatment with any other drug modifying the testosterone level or function.
Is considered to be a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy, within 6 months after Visit 1.
Has a history of severe asthma requiring daily treatment with inhalation steroids, angioedema or anaphylactic reactions.
Has hypersensitivity towards any component of the investigational product.
Has had a cancer disease within the last 10 years except for prostate cancer, and surgically removed basocellular or squamous cell carcinoma of the skin.
Has a clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, dermatological or infectious disorder or any other condition, including excessive alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the study, as judged by the investigator.
Any clinically significant laboratory abnormalities which, in the judgment of the investigator, would interfere with the patient's participation in this study or evaluation of study results (liver transaminases and bilirubin must be within normal limits).
Has a mental incapacity or language barrier precluding adequate understanding or co-operation.
Intervention: Degarelix
Trial phase: Phase 2
ATC code: L02BX02
SMILES: CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Degarelix 160 mg (40 mg/mL)
Eligibility criteria:
Inclusion Criteria:

Each patient must meet the following inclusion criteria before entry into the study:

Has given written consent before any study related activity is performed. A study related activity is defined as any procedure that would not have been performed during the normal management of the patient.
Has had sufficient testosterone suppression (as defined in the withdrawal criteria of FE200486 CS06) for at least 28 days.

Exclusion Criteria:

Any patient meeting any of the following exclusion criteria will not be entered into the study:

Has been withdrawn from Study FE200486 CS06 due to an adverse event, failure to achieve at least 28 days of testosterone suppression, insufficient prostate-specific antigen (PSA) suppression as defined in Study FE200486 CS06 in the absence of concomitant rise in testosterone level or non-compliance with protocol required procedures.
Requires hormonal therapy for neoadjuvant purposes.
Requires treatment with any other drug modifying the testosterone level or function.
Is considered to be a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy, within 6 months after Visit 1.
Has a history of severe asthma requiring daily treatment with inhalation steroids, angioedema or anaphylactic reactions.
Has hypersensitivity towards any component of the investigational product.
Has had a cancer disease within the last 10 years except for prostate cancer, and surgically removed basocellular or squamous cell carcinoma of the skin.
Has a clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, dermatological or infectious disorder or any other condition, including excessive alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the study, as judged by the investigator.
Any clinically significant laboratory abnormalities which, in the judgment of the investigator, would interfere with the patient's participation in this study or evaluation of study results (liver transaminases and bilirubin must be within normal limits).
Has a mental incapacity or language barrier precluding adequate understanding or co-operation.
Intervention: Sildenafil
Trial phase: Phase 1 | Phase 2
ATC code: G01AE10 | G04BE03
SMILES: CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: A single vaginal dose of sildenafil citrate 100 mg.
Eligibility criteria:
Inclusion Criteria:

Primary dysmenorrhea at current visit, with a visual analogue scale (VAS) score of >35; pain defined as moderate or severe on a categorical of none, mild, moderate, severe.

Exclusion Criteria:

Secondary dysmenorrhea
Any current medication
Serious medical condition